Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02358187 · ClinicalTrials.gov registry record · Phase 2
A Vaccine Trial for Low Grade Gliomas
A Phase 2 study of Low Grade Glioma, sponsored by James Felker.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT02358187 is a Phase 2 study of Low Grade Glioma that is actively recruiting participants, run by James Felker. The registered enrollment target is 25 participants, below the 113-participant average among 23 other Low Grade Glioma trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02358187, a Phase 2 study of Low Grade Glioma, is actively recruiting participants, sponsored by James Felker.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
The study will assess the immunogenicity, safety and preliminary clinical efficacy of the glioma associated antigen (GAA)/tetanus toxoid (TT) peptide vaccine and poly-ICLC in HLA-A2+ children with unresectable low-grade gliomas that have received at least two chemotherapy/biologic regimens. Radiation therapy counts as one biologic regimen, but patients may not have received radiation to the index lesion within 1 year of enrollment.
Conditions Studied
Interventions
- BIOLOGICAL Experimental: HLA-A2 Restricted Glioma Antigen-Peptides with Poly-ICLC
Study Locations (1)
Pennsylvania
- Children's Hospital of Pittsburgh of UPMC - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2015-01 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02358187
The ClinicalTrials.gov registry entry for NCT02358187 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 113-participant average among 23 other Low Grade Glioma trials with a reported enrollment target (78% lower). The listed sponsor is James Felker, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Low Grade Glioma appearing as the primary indexed condition, and to 1 intervention - of which Experimental: HLA-A2 Restricted Glioma Antigen-Peptides with Poly-ICLC is the first listed.
NCT02358187 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02358187 about?
NCT02358187 is a clinical study titled "A Vaccine Trial for Low Grade Gliomas". The study will assess the immunogenicity, safety and preliminary clinical efficacy of the glioma associated antigen (GAA)/tetanus toxoid (TT) peptide vaccine and poly-ICLC in HLA-A2+ children with unresectable low-grade gliomas that have received at least two chemotherapy/biologic regimens. Radiatio...
What is the current status of trial NCT02358187?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2015-01. Estimated completion is 2028-12-31.
What conditions does trial NCT02358187 study?
This clinical trial studies the following conditions: Low Grade Glioma.
What interventions are being tested in trial NCT02358187?
The interventions under investigation include: Experimental: HLA-A2 Restricted Glioma Antigen-Peptides with Poly-ICLC (BIOLOGICAL).
Who is sponsoring clinical trial NCT02358187?
This trial is sponsored by James Felker, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02358187 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Low Grade Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial
RECRUITING · Phase 2
-
A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
RECRUITING · Phase 2
-
Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas
RECRUITING · Phase 2
-
Vinblastine +/- Bevacizumab in Children With Unresectable or Progressive Low Grade Glioma (LGG)
ACTIVE NOT RECRUITING · Phase 2
-
Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.